Clinical trial · Interventional
Pinverin Application Trial to Reduce Bowel Uptake of FDG (Fluorodeoxyglucose)
Clinical Trial of Pinverin (Pinaverium Bromide) to Reduce Bowel Uptake of FDG in a Variety of Cancer Patients Who Undergo FDG PET/CT
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
1. Background 1. PET/CT (positron emission tomography/computed tomography) using FDG (fluorodeoxyglucose) is widely used for evaluation of cancer patients. 2. Bowel uptake of FDG is a serious problem that hampers the proper reading of PET/CT. 3. There is no widely-accepted method to reduce the bowel FDG uptake. 2. Purpose 1. To know whether pinverin (pinaverium bromide) application during PET/CT can reduce bowel uptake of FDG. 2. Pinverin is a calcium-channel blocker that ameliorates the bowel contraction. 3. Pinverin may be useful to reduce bowel FDG uptake by ameliorating the bowel contraction during PET/CT acquisition. 3. Method 1. Intervention versus control: administration of single tablet of pinverin (50mg) perorally versus simple water (\~100mL). 2. Timing of administration: At the time of FDG injection. PET/CT images will be acquired 1hr post FDG injection. 4. Primary outcome 1. SUV (standardized uptake value) difference between pinverin administered patient group versus control group. 2. SUV (standardized uptake value) is calculated as: (decay corrected radioactivity in mCi/mL) x (body weight in g) / (injected radioactivity in mCi)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| pinaverium bromide | Drug | — | UNRESOLVED |
| water | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- pinaverium bromide
- description
- pinaverium bromide 50 mg tablet per oral administration one time
- interventionNames
- Drug: pinaverium bromide
- type
- PLACEBO_COMPARATOR
- label
- water
- description
- water \~100mL
- interventionNames
- Drug: water
Primary outcomes (1)
- measure
- SUV (standardized uptake value)
- timeFrame
- 1 hour after FDG (the radiopharmaceutical for PET/CT) injection
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Any cancer patients * Candidate of positron emission tomography/computed tomography Exclusion Criteria: * Diabetes mellitus * Inflammatory bowel disease * Irritable bowel syndrome * Peritoneal carcinomatosis * Peritonitis * Abdominal pain * Diarrhea * Medical test requiring bowel preparation within 1 month * History of abdominal surgery * Symptom or sign of colitis * Pregnancy or lactation * Hypersensitivity to pinaverium bromide * Lactate intolerance * Anit-depressant medication
References
Publications (0)
Data not yet available